Products
Lurasidone is commercially available in the form of film-coated tablets (Latuda). It has been approved in many countries since 2013. In the United States, it was registered as early as 2010.
Structure and properties
Lurasidone (C28H36N4O2S, Mr = 492.7 g/mol) belongs to the benzoisothiazoles. It exists as a white powder that is sparingly soluble in water. Lurasidone is structurally related to ziprasidone.
Effects
Lurasidone (ATC N05AE05) has antipsychotic properties. The effects are due to antagonism at central dopamine D2 receptors and serotonin 5HT2A receptors. Lurasidone has a long half-life of approximately 18 hours.
Indications
For the treatment of patients with schizophrenia.
Dosage
According to the professional information. Tablets are taken once daily with food.
Contraindications
- Hypersensitivity
- Combination with strong CYP3A4 inhibitors and strong CYP3A4 inducers.
For complete precautions, see the drug label.
Interactions
Lurasidone is metabolized primarily by CYP3A4 and appropriate drug-drug interactions are possible (see above). Lurasidone should not be combined with alcohol.
Adverse effects
The most common potential adverse effects include drowsiness, motor agitation, nausea, parkinsonism, and agitation.
